Cambridge Innovation Capital (CIC) launches £100M ($126M) Opportunity Fund to back later-stage deep tech and life sciences startups in Cambridge. Anchored by Aviva Investors and British Patient Capital, the fund aims to fill the U.K.'s scale-up capital gap. Early investments include Pragmatic Semiconductor and Riverlane. CIC has invested $757M in 40+ companies, with past exits like Gyroscope Therapeutics ($1.5B sale to Novartis) and PetMedix ($285M acquisition by Zoetis).